GSK Worthing shares in £200 million new investment

GSK Worthing shares in £200 million new investment

 

GSK Worthing shares in a series of investments totalling approximately £200 million announced by the company today (Wednesday December 11th). The investments support the delivery of the company’s pipeline of new medicines.

Worthing will be upgraded with new state-of-the-art equipment. A new bulk sterile building and filling line will be built for the company’s leading antibiotic medicine AugmentinTM, which is exported to 150 countries.

Roger Connor, GSK’s President of Global Manufacturing and Supply, said:“The establishment of the Patent Box has transformed how we see the UK as a place to invest. As a result, last year we announced we were building our first new factory in the UK for 40 years. The investments announced today are in addition to that and will allow us to harness new technologies that have the potential to deliver a step-change in how we make medicines. These new technologies could significantly reduce costs, improve quality and enable the manufacture of medicines in weeks rather than years and I am delighted that we have been able to bring these investments to the UK.” 

Jeremy Hunt, Health Secretary, said: “On the day when we are bringing together the health leaders of the developed world, researchers and pharmaceutical countries to launch the global fight against dementia, it is great to see GSK investing more money and resources into UK life sciences. GSK’s decision to invest in the UK shows we are creating the right conditions for global investment, leading to job creation and growth, as well as maintaining the UK’s place as a world leader in innovation.”

GSK’s Worthing site has more than 950 employees making both active ingredients and finished medicines which are supplied to 157 markets worldwide. In the last full year the site supplied more than 100 million packs of medicines and more than 1,000 tonnes of bulk products. ,